Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis, also known as non-alcoholic steatohepatitis, and other diseases with significant unmet medical needs, announced the results of the votes of its Combined Shareholders’ Meeting.
June 21, 2024
· 13 min read